Strategic Science & Technologies, LLC

Strategic Science & Technologies, LLC (SST) is a privately funded, clinical-stage biotechnology company based in Cambridge, Massachusetts, in the United States. The company describes itself as having an innovative topical drug delivery technology that is used to formulate known active pharmaceutical ingredients. According to its own materials, SST's patented delivery technology is designed to provide targeted local delivery of active pharmaceutical ingredients at therapeutic levels, and the company has advanced three programs into clinical trials. SST's most visible development program concerns a topical formulation of sildenafil, known as Sildenafil Cream, 3.6%, which is being developed as a potential therapy for Female Sexual Arousal Disorder (FSAD). The company has stated that it is seeking to become the first FDA-approved product for the treatment of FSAD. This program has been advanced through a license and collaboration agreement with Daré Bioscience, Inc., under which the two companies have announced milestones including the effective license and collaboration agreement for topical sildenafil for FSAD, the initiation of a content validity study for Sildenafil Cream, 3.6%, and enrollment in a thermography feasibility study. As a clinical-stage company, SST's activities center on research and development rather than commercial product sales. Its business model combines proprietary formulation and delivery technology with partnerships and licensing arrangements to move drug candidates through clinical development toward potential regulatory approval. The company is privately funded and is not listed on a public stock exchange. Because SST is a privately held, development-stage enterprise, detailed public information about its founding, ownership structure, and financial history is limited. Its public profile rests primarily on its topical drug delivery platform and its collaboration with Daré Bioscience on the topical sildenafil program for FSAD.

Strategic Science & Technologies, LLC (SST) is a privately funded, clinical-stage biotechnology company located in Cambridge, Massachusetts, in the United States. The company has developed an innovative topical drug delivery technology used to formulate known active pharmaceutical ingredients. According to the company, its patented delivery technology provides targeted local delivery of active pharmaceutical ingredients at therapeutic levels, and SST has advanced three programs into clinical trials. The company's most prominent development effort is a topical formulation of sildenafil, Sildenafil Cream, 3.6%, being developed as a potential therapy for Female Sexual Arousal Disorder (FSAD). SST has stated that it is seeking to become the first FDA-approved product for the treatment of FSAD. This program has been pursued through a license and collaboration agreement with Daré Bioscience, Inc. Publicly announced milestones in this collaboration include the effective license and collaboration agreement for topical sildenafil for FSAD, the initiation of a content validity study for Sildenafil Cream, 3.6%, and enrollment in a thermography feasibility study. As a clinical-stage company, SST's history is primarily one of research, formulation development, and clinical advancement rather than commercial product launches. Detailed information about its founding date, founders, ownership, and financing history is not available in the supplied evidence.

• SST and Daré Bioscience, Inc. enter an effective license and collaboration agreement for topical sildenafil for Female Sexual Arousal Disorder.

  [1]Strategic Science & Technologies official websitestrategicscience.com
• SST and Daré Bioscience announce the initiation of a content validity study for Sildenafil Cream, 3.6%.

  [1]Strategic Science & Technologies official websitestrategicscience.com
• SST and Daré Bioscience announce enrollment in a thermography feasibility study.

  [1]Strategic Science & Technologies official websitestrategicscience.com

Clinical-stage biotechnology company focused on patented topical drug delivery of known active pharmaceutical ingredients, seeking to become the first FDA-approved product for Female Sexual Arousal Disorder.

• Sildenafil Cream, 3.6%

  An investigational topical formulation of sildenafil being developed as a potential therapy for Female Sexual Arousal Disorder (FSAD).

• Topical drug delivery technology

  A patented delivery technology that provides targeted local delivery of active pharmaceutical ingredients at therapeutic levels.

1. 1Strategic Science & Technologies official websitestrategicscience.com
2. 2Wikidata: Strategic Science & Technologies (United States)wikidata.org